Total Body Photography and Sequential Digital Dermoscopy Imaging for Melanoma Surveillance in Patients Starting Natalizumab for Multiple Sclerosis by Nussinow, Tyler, BA et al.
Journal of Maine Medical Center 
Volume 3 Issue 2 Article 10 
2021 
Total Body Photography and Sequential Digital Dermoscopy 
Imaging for Melanoma Surveillance in Patients Starting 
Natalizumab for Multiple Sclerosis 
Tyler Nussinow BA 
Maine Medical Partners Dermatology 
Et al. 
Follow this and additional works at: https://knowledgeconnection.mainehealth.org/jmmc 
 Part of the Dermatology Commons, and the Neurology Commons 
Recommended Citation 
Nussinow, Tyler BA; Robinson, Amanda NP; Beretich, Biljana MD; Stevens, Kathryn NP; and Seiverling, 
Elizabeth MD (2021) "Total Body Photography and Sequential Digital Dermoscopy Imaging for Melanoma 
Surveillance in Patients Starting Natalizumab for Multiple Sclerosis," Journal of Maine Medical Center: 
Vol. 3 : Iss. 2 , Article 10. 
Available at: https://knowledgeconnection.mainehealth.org/jmmc/vol3/iss2/10 https://doi.org/10.46804/
2641-2225.1083 
The views and thoughts expressed in this manuscript 
belong solely to the author[s] and do not reflect the 
opinions of the Journal of Maine Medical Center or 
MaineHealth. 
This Innovation Highlight is brought to you for free and 
open access by Maine Medical Center Department of 
Medical Education. It has been accepted for inclusion in 
the Journal of Maine Medical Center by an authorized 
editor of the MaineHealth Knowledge Connection. For 
more information, please contact Dina McKelvy 
mckeld1@mmc.org. 
Total Body Photography and Sequential Digital Dermoscopy Imaging for 
Melanoma Surveillance in Patients Starting Natalizumab for Multiple Sclerosis 
Authors 
Tyler Nussinow BA, Amanda Robinson NP, Biljana Beretich MD, Kathryn Stevens NP, and Elizabeth 
Seiverling MD 
This innovation highlight is available in Journal of Maine Medical Center: 
https://knowledgeconnection.mainehealth.org/jmmc/vol3/iss2/10 
INNOVATION HIGHLIGHT
Total Body Photography and Sequential Digital 
Dermoscopy Imaging for Melanoma Surveillance in Patients 
Starting Natalizumab for Multiple Sclerosis
Tyler Nussinow, BA,¹ Amanda Robinson, NP,¹ Biljana Beretich, MD,² Kathryn Stevens, NP,¹ Elizabeth 
Seiverling, MD¹  
¹Maine Medical Partners Dermatology, Maine Medical Center, Portland ME, ²Maine Medical Partners Neurology, Maine 
Medical Center, Portland ME
Introduction:  Natalizumab is an integrin receptor antagonist that has been approved by the Food and Drug 
Administration to treat multiple sclerosis and Crohn’s disease. The drug has been linked to an increased 
risk of melanoma. This brief report highlights an innovative clinical approach for monitoring the skin of 
patients prescribed natalizumab.
Methods:  We include 2 cases from our skin oncology clinic and a literature review on the incidence of melanoma 
in patients prescribed natalizumab between 2004 and 2019.
Results:  In addition to our 2 cases, we found 193 reports of patients with melanoma who were prescribed 
natalizumab. We propose an innovative and proactive approach using total body photography and 
sequential digital dermoscopy imaging before starting and while treating patients with natalizumab.
Discussion:  Given the mechanism of action of natalizumab, many of the melanomas diagnosed likely arose from 
preexisting melanocytic nevi. Using total body photography before starting this high-risk medication and 
then sequential digital dermoscopy imaging will increase a dermatologist’s ability to recognize new and 
preexisting skin lesions that have evolved since the patient began taking natalizumab.
Conclusions:  Using the latest non-invasive technology to detect skin cancer supports systematic and objective 
monitoring of changing melanocytic growths in patients prescribed natalizumab, resulting in earlier 
detection of melanoma and greater cure rates. 
Keywords:  total body photography, dermoscopy, melanoma, multiple sclerosis, natalizumab, Crohn’s disease
Natalizumab (Tysabri) is a recombinant, humanized monoclonal antibody that binds to α4β1-integrin and blocks its interaction 
with vascular cell adhesion molecule-1. As a result, 
leukocyte migration into brain tissue is inhibited, 
reducing inflammation and preventing the formation 
of lesions.1 Natalizumab is approved by the Food 
and Drug Administration (FDA) to treat multiple 
sclerosis (MS) and Crohn’s disease. Typically, 
this drug is given via a 1-hour infusion every 4 
weeks.2 On average, patients receive natalizumab 
treatments over 30 infusions, or approximately 2.5 
years.3
Natalizumab comes with a black box warning 
highlighting the increased risk of progressive 
multifocal leukoencephalopathy, a viral infection 
of the brain that can lead to death.2 Yet, the FDA 
prescribing information does not mention that 
numerous reports correlated natalizumab and the 
development of melanoma, a potentially deadly skin 
cancer if not caught early.4,5,6 In one study from Italy, 
patients receiving natalizumab for MS were 3 times 
more likely to develop melanoma than the general 
population.7 It is still unclear how natalizumab 
promotes melanoma development. A recent study 
by Carbone et al did not find a direct link between 
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natalizumab treatment and the development of 
cutaneous melanoma.8 Rather, natalizumab may 
indirectly favor melanoma progression by impairing 
the function of natural killer cells, therefore 
modifying the tumor microenvironment toward 
immune suppression and proangiogenesis.3
This brief report highlights an innovative clinical 
approach for monitoring the skin in patients 
prescribed natalizumab.
METHODS
Maine Medical Partners Dermatology has a 
dedicated skin oncology clinic with cutting-edge 
technology (not widely available) to support their 
care of patients prescribed high-risk medications or 
who have a history of melanoma or multiple non-
melanoma skin cancers. One type of this technology 
is total body photography (TBP). High-quality, 
whole-body images of the patient’s pigmented skin 
lesions are taken via FotoFinder, a computerized 
system that maps moles. This technology also 
allows for high-resolution digital dermoscopy with 
up to 140× magnification.9 Dermoscopy supports 
in vivo evaluation of colors and structures of the 
epidermis and parts of the dermis not visible to 
the naked eye.10 Sequential digital dermoscopy 
imaging (SDDI) offers a time-lapse comparative of 
pigmented skin lesions at different time intervals, 
supporting detection of changes as subtle as 1/10 
millimeter.11  Another type of cutting-edge technology 
is reflectance confocal microscopy (RCM). This non-
invasive technique supports analysis of growths at 
the cellular level in vivo. RCM and TBP have been 
shown to aid in melanoma detection.
We include 2 case reports from our skin oncology 
clinic. Formal written consent was obtained. We 
also reviewed the literature for the incidence of 
melanoma in patients prescribed natalizumab. 
Information on natalizumab-associated melanomas 
was identified by examining peer-reviewed literature 
in PubMed from 2004 to 2019 using the keywords 
“natalizumab” and “melanoma.” Articles reviewed 
were limited to the English language.
Based on our findings of numerous reports 
describing natalizumab-associated melanomas, 
we partnered with the Center for Comprehensive 
MS Care at Maine Medical Partners Neurology 
to develop an innovative management strategy 
for monitoring skin cancer. This center cares for 
approximately 1250 patients with MS and 280 
patients with other demyelinating diseases. In 




Case 1: A 35-year-old female with no prior history 
of skin cancer was given natalizumab for MS for 
approximately 3 years before she presented with an 
enlarging pigmented growth on the lateral aspect of 
her right thigh (Figure 1A). The growth had been 
present since her childhood and became darker 
and larger shortly after she started treatment with 
natalizumab. Dermoscopy revealed a disorganized 
pattern within a melanocytic growth. Also present 
were shiny white structures, a blue-gray veil, 
and dotted vessels (Figure 1B). Due to concern 
for melanoma, she underwent a saucerization 
skin biopsy for depth and breadth under local 
anesthesia. The pathology report showed a 
superficial spreading malignant melanoma, stage 
1b (0.8 mm, no ulceration), with peripheral and 
deep margins free of involvement. Her treatment 
with natalizumab was stopped and, per current 
guideline recommendations, she was referred to 
surgical oncology for a wide local excision and 
sentinel lymph node biopsy.12 Negative margins 
were achieved and the results of the sentinel lymph 
node biopsy were negative. She is currently taking 
dimethyl fumarate (Tecfidera) for MS. To date, since 
stopping natalizumab, the patient has not presented 
with new skin lesions concerning for melanoma.
Case 2: A 37-year-old female with no prior history 
of skin cancer was given natalizumab for MS for 
6 months before she developed several new 
melanocytic growths on her torso and bilateral lower 
extremities. Natalizumab was discontinued after 6 
doses of therapy. Four months later, a melanoma 
was diagnosed on her back. Similar to Case 1, her 
treatment for MS was initially switched to Tecfidera. 
The patient has since undergone several changes 
in therapy and her disease continues to progress. 
To date, the patient has had no reports of new or 
changing nevi concerning for skin cancer.
Literature review (Table 1)
In addition to 2 cases from our skin oncology clinic, 
we found 193 reports of melanoma associated with 
natalizumab.4,5,6
2
Journal of Maine Medical Center, Vol. 3 [2021], Iss. 2, Art. 10
https://knowledgeconnection.mainehealth.org/jmmc/vol3/iss2/10
DOI: 10.46804/2641-2225.1083
Sabol et al detailed an individual case report and 
included findings from both the FDA’s Adverse 
Event Reporting System and their own literature 
search. The impetus behind their investigation 
stemmed from the development of a deadly urethral 
melanoma in a 43-year-old female with MS taking 
natalizumab for more than 2 years. Before April  1, 
2014, there were 137 cases of natalizumab-
associated melanomas reported to the Adverse 
Event Reporting System. An additional 45 cases 
were reported between April 1, 2014 and June 30, 
2016. Of the cases reported up to April 2014, most 
were females being treated with natalizumab for 
MS. The median age at melanoma diagnosis was 
45. Diagnosis was typically made within 2 years of 
natalizumab treatment. Most cases of natalizumab-
associated melanoma were treated successfully 
with surgery. Nine patients (6.6%) died from 
melanoma complications.
In the literature, Sabol et al found 7 additional cases 
of patients with MS who were taking natalizumab 
and developed melanoma, confirmed by biopsy. All 
but 1 case involved a female. The median age was 
41 years, and the melanoma diagnosis occurred 
after a median of 12 doses of natalizumab. These 7 
published cases include those reported by Vavricka 
et al and Mullen et al, which were part of our 
literature review.
Vavricka et al reported 1 case of a 41-year-old 
female with a history of atypical nevi who was taking 
natalizumab for MS for approximately 15 months. 
At this time, she developed a rapidly growing nevus 
on her upper arm that was later diagnosed as 
melanoma in situ and was excised successfully.
Mullen et al wrote a letter to the editor of the New 
England Journal of Medicine highlighting 2 cases 
of natalizumab-associated melanoma in women in 
their mid-forties with a diagnosis of MS. One patient 
was a 46-year-old female who noticed a rapidly 
changing nevus on her shoulder shortly after taking 
her first dose of natalizumab. The biopsy revealed a 
thick, non-ulcerated melanoma with metastases to 
the lymph nodes. The second patient was a 45-year-
old female who developed ocular melanoma from 
a longstanding ocular nevus after taking several 
doses of natalizumab.
Innovative proposal
We propose an innovative and proactive approach 
using TBP and SDDI before starting and while 
treating patients with natalizumab.
1. Before starting natalizumab, the patient should 
be seen by a dermatologist for a full-body skin 
examination with dermoscopy.
a. Lesions that are worrisome for melanoma 
should be either biopsied or further evaluated 
using RCM.
2. The patient should undergo baseline TBP with 
digital dermoscopic imaging.
3. The patient should be evaluated against 
baseline images every 4 to 6 months. New or 
changing growths should be biopsied.
We suspect our patients (and many of the reported 
cases) had tenuous melanocytic growths before 
starting natalizumab treatment, and the medication 
enabled the progression by adversely impacting 
A B
Figure 1. Melanocytic Growth in Patient Prescribed Natalizumab. (A) Clinical photo and (B) polarized 
dermoscopic image of 1.6 cm melanocytic growth on lateral aspect of right thigh
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DISCUSSION
The majority of melanomas diagnosed in patients 
taking natalizumab develop within approximately 2 
years of beginning therapy, as was shown with Case 
2.4 When melanoma is caught early, cure rates are 
nearly 100%.13  For patients prescribed natalizumab, 
current recommendations include a full-body skin 
examination conducted by a dermatologist every 6 
months after starting treatment.4 However, given the 
mechanism of action of natalizumab, many of the 
melanomas diagnosed likely arose from preexisting 
melanocytic nevi, as seen in Case 1. 
Table 1. Literature Review of Case Reports of Natalizumab-Associated Melanomas
Author Age, y Sex
# of doses at 
melanoma 
diagnosis
Clinical features Other information




(estimated 2.2 y of 
treatment)
Polyp in distal urethra 
positive for melanoma.




38 M 5 -- Patient died from melanoma.
39 F 5
After 10 months, ulcerated 
and ablated. 1.6 mm 
thickness and Clark level 
IV. No metastasis to lymph 
nodes.
Therapy stopped after 
16 doses.
38 F 77
Malignant melanoma. Clark 
level III and Breslow index 
0.5 mm.
No evidence of 
metastasis.
48 F 35
5 months after last dose, 
noticed enlarging mole on 
right shin. Lesion was flat 
with a dark center.









melanoma from a dysplastic 
nevus on upper arm.
Had many atypical 
moles for years. 
Melanoma occurrence 
close to therapy start.
Sabol et 
al (2017), 
Mullen et al 
(2008)
46 F 1
Mole on shoulder for a long 
time before melanoma. 







Ocular melanoma. Long 
history of mole in posterior 
eye. Mole was unchanged 
for 6 years before therapy.
Family history of 
melanoma.
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immune surveillance. Thus, instead of waiting 
until a patient has already started treatment with 
natalizumab, we propose an innovative and 
proactive approach using TBP and SDDI. Much 
literature supports our assertion that TBP and SDDI 
will increase a dermatologist’s ability to recognize 
new and preexisting skin lesions that have evolved 
since a patient began taking natalizumab.14,15,16,17 In 
patients over age 50, 30% of new growths identified 
with TBP are melanoma.6 Furthermore, using TBP 
and SDDI, one study monitored 11,396 lesions on 
629 patients at high risk for developing melanoma.14 
A total of 98 melanomas (8.5% of excised lesions) 
were diagnosed in 78 patients (12.6%). These 
lesions were identified at an early stage; 53 were 
superficial (in situ), 45 had a Breslow index (depth of 
tumor invasion) of < 1.0 mm (median 0.5 mm), and 
all were without ulceration (presence of ulceration 
portends a higher risk for metastasis).14
CONCLUSIONS
Patients prescribed natalizumab have an increased 
risk for developing melanoma from new and 
preexisting skin lesions. Proactive TBP and SDDI 
using our innovative approach supports improved 
monitoring of melanocytic skin growths in a 
systematic, objective way that may detect melanoma 
at earlier stages in high-risk patients. For optimal 
outcomes, a partnership is essential between the 
neurologist who prescribes natalizumab and the 
dermatologist who monitors the skin. 
Lastly, this brief report is timely. In October 2020, the 
Journal of the American Academy of Dermatology 
issued a statement encouraging dermatologists to 
use TBP with SDDI and RCM to aid in detecting 
skin melanoma.18 The skin oncology clinic at Maine 
Medical Partners offers all these cutting-edge 
technologies.
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